News: Owners Developers & Managers
Posted: September 8, 2023
J. Calnan & Associates, Inc., LeftField Project Management, Hammel, Green & Abrahamson, and AHA Engineers complete Biocytogen Pharmaceuticals project
Waltham, MA J. Calnan & Associates, Inc. (JC&A) has completed a project for Biocytogen Pharmaceuticals. The grand opening of Biocytogen’s new 37,000 s/f facility, marks a notable achievement in advancing research and development in the global biomedical sector.
JC&A has worked alongside LeftField Project Management, Hammel, Green & Abrahamson, and AHA Engineers to bring this project to life. Located at 300 Third Ave., this facility integrates BSL2 lab & vivarium space with sophisticated class A office space, fostering synergy and innovation among researchers and office workers.
The collaboration signifies a significant milestone in the field of biomedical research, propelling Biocytogen Pharmaceuticals as a leader in integrated solutions for next-generation antibody drug development. The facility’s highlights include a climate-controlled 4,000 cage vivarium, advanced cell culture and procedure suites, and an open-concept design that encourages cross-disciplinary collaboration among teams and partners.
This achievement solidifies Biocytogen’s commitment to providing exceptional preclinical contract research services and distributing specialized animal model products (BioMice). These products are increasingly sought after by clients spanning North America and Europe. With an extensive portfolio encompassing over 500 strains of specialized mice, Biocytogen has positioned itself as a global frontrunner in humanized animal models. The facility’s cutting-edge resources, such as the flagship RenMab model and second-generation RenMice-based platforms, empower researchers to explore novel antibody and cell-based therapeutics with diverse applications.
Jeff Cameron, partner and project executive at JC&A, expressed his enthusiasm, said, “The completion of Biocytogen’s new facility is a testament to JC&A’s unwavering commitment to innovation in building within the life sciences sector. Our partnership with Biocytogen highlights our dedication to shaping the future of biomedical research by providing exceptional environments for groundbreaking discoveries.”
Biocytogen is the latest project in a portfolio that features complex projects for clients including Merck & Co, Biogen, Schrodinger, Inc, Lyra Therapeutics, TScan Therapeutics, and Affinia Therapeutics.
MORE FROM Owners Developers & Managers
Elm Grove Companies breaks ground on $20 million - The Rapids On Cocheco
Rochester, NH Real estate development firm, Elm Grove Companies, has started construction of The Rapids On Cocheco, an approved 52-unit workforce housing community at 29 Wadleigh Rd. This will be the company’s ninth venture in the affordable housing arena with other affordable properties in the state totaling 430 apartments
.jpg)
.png)
Columns and Thought Leadership
IREM President’s Message: Fostering community connections during the holiday season
The holidays are again taking center stage, and with them comes an opportunity for multifamily communities to connect with the businesses and organizations in their cities and towns, fostering a sense of unity and generosity during this giving season
Selecting the right façade installation firm - by Steven Powell
As the owner of a major new property being developed, or an existing large building preparing for major renovation, you want your design and construction team to have the right experience, capabilities, and expertise to match the project demands. A critical member of this team will be the façade installation specialty firm, since the quality of this installation will impact
Recently passed legislation creates opportunities to meet CT’s changing energy needs - by Klein and Feinn
For decades, New England has had a summer-peaking power system, where the greatest energy use occurs on the hottest and most humid days, due to widespread use of air conditioning. But by the mid-2030s, electrification of the heating sector likely will result in a winter peak that’s higher than the summer peak.
